v3.26.1
Segment Performance Measures and Expenses (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Significant Expense Categories and Consolidated Net Loss

The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

 

                 
   For the three months ending March 31, 
   (In thousands)   Change Increase (Decrease) 
   2026   2025         
Operating Expenses:                    
Clinical Research                    
OVATION 2 and MRD Trials  $105   $134   $(29)   (21.6)%
OVATION 3 Trial   101    80    21    26.3%
PlaCCine Vaccine Phase 1 Trial   3    58    (55)   (94.6)%
Other Clinical and Regulatory   589    574    15   2.6%
Subtotal   798    846    (48)   (5.7)%
Non-Clinical R&D and CMC                    
OVATION Program   1,293    913    380    41.6%
Manufacturing (CMC)   247    406    (159)   (39.2)%
Subtotal   1,540    1,319    221    16.8%
                     
Research and development expenses   2,338    2,165    173    8.0%
General and administrative expenses   1,969    1,980    (11

)

   (0.6)%
Total operating expenses   4,307    4,145    162    3.9%
                     
Loss from operations  $(4,307)  $(4,145)  $(162)   (3.9)%